You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma - 2022
Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Gene Expression Profiling
  • Gene expression profile
  • Shanghai, Shanghai, China
    Yian Zhang
2022-03-31
Mar 31, 2022
S
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma - 2021
Completed
Has Results
  • Lymphoma, Large B-Cell, Diffuse
  • FDG PET radiomic feature evaluation
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
2021-09-27
Sep 27, 2021
H
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA
Recruiting
  • Lymphoma, Large B-Cell, Diffuse
    • Copenhagen, Denmark
      Department of Hematology, Rigshospitalet
    2022-01-12
    Jan 12, 2022
    W
    Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma - 2022
    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • Saint Louis, Missouri
    • +1 more
    2022-02-16
    Feb 16, 2022
    R
    PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
    Recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • +2 more
    • PD-1 Inhibitor Tislelizumab maintenance therapy
    • Shanghai, Shanghai, China
      Ruijin Hospital
    2021-11-14
    Nov 14, 2021
    U
    Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas - 2021
    Completed
    • Lymphoma, B-Cell
      • Montpellier, France
        Uh Montpellier
      2021-11-12
      Nov 12, 2021
      P
      Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
      Recruiting
      • Lymphoma, Large B-Cell, Diffuse
      • Digital Health Coaching
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      2022-01-19
      Jan 19, 2022
      U
      Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • (no location specified)
      2022-02-02
      Feb 2, 2022
      N
      T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas - 2022
      Completed
      • Lymphoma, Large-Cell, Anaplasitc
      • +4 more
      • Anti-CD30-CAR T cells
      • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-01-27
      Jan 27, 2022
      C
      Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
      Not yet recruiting
      • Lymphoma, Non-Hodgkin
      • +3 more
        • (no location specified)
        2021-07-20
        Jul 20, 2021
        U
        Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab
        Recruiting
        • Pneumococcal Infections
        • Lymphoma, Large B-Cell, Diffuse
        • Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
        • Tours, France
          GYAN
        2021-05-17
        May 17, 2021
        R
        Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
        Not yet recruiting
        • Diffuse Large B Cell Lymphoma
          • (no location specified)
          2021-12-27
          Dec 27, 2021
          N
          EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
          Active, not recruiting
          • Lymphoma, AIDS-related
          • Lymphoma, Large B-Cell, Diffuse
          • Rituximab
          • +2 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          2022-03-11
          Mar 11, 2022
          J
          Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
          Available
          • Lymphoma, Large B-Cell, Diffuse
          • Nonconforming Lisocabtagene Maraleucel
          • (no location specified)
          2022-01-11
          Jan 11, 2022
          F
          ZR-CHOP in DLBCL With Specific Gene Abnormality
          Recruiting
          • Diffuse Large B Cell Lymphoma
          • Shanghai, Shanghai, China
            Fudan University Shanghai Cancer Center
          2022-03-13
          Mar 13, 2022
          T
          Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma
          Active, not recruiting
          • Lymphoma, B-Cell
          • San Antonio, Texas
            Mays Cancer Center, UT Health San Antonio
          2022-03-09
          Mar 9, 2022
          A
          Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
          No longer available
          • Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
          • Loncastuximab Tesirine
          • (no location specified)
          2021-05-10
          May 10, 2021
          C
          Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
          Not yet recruiting
          • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
          • With and Without MyD88 and/or CD79B Mutations
          • (no location specified)
          2022-04-01
          Apr 1, 2022
          B
          Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
          Not yet recruiting
          • Relapsed Diffuse Large B-cell Lymphoma
          • loncastuximab tesirine
          • Detroit, Michigan
            Barbara Ann Karmanos Cancer Institute
          2022-01-24
          Jan 24, 2022
          U
          Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma - 2021
          Completed
          • Diffuse, Large B-Cell, Lymphoma
          • Los Angeles, California
            USC Norris Comprehensive Cancer Center
          2021-11-15
          Nov 15, 2021
          C
          18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
          Recruiting
          • Diffuse Large B Cell Lymphoma
          • 18F-FDG PET SCAN
          • MRI DIFFUSION
          • Nice, France
            Centre antoine-LACASSAGNE
          2021-11-09
          Nov 9, 2021
          R
          PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT
          Not yet recruiting
          • Lymphoma, Large B-Cell, Diffuse
          • +2 more
          • PD-1 Inhibitor Tislelizumab maintenance therapy
          • Shanghai, Shanghai, China
            Ruijin Hospital
          2021-03-15
          Mar 15, 2021
          D
          Copanlisib Plus Venetoclax in R/R DLBCL
          Recruiting
          • Diffuse Large B Cell Lymphoma
          • +2 more
          • Boston, Massachusetts
            Dana-Farber Cancer Institute
          2021-09-08
          Sep 8, 2021
          M
          Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
          Active, not recruiting
          • Large B-Cell Diffuse Lymphoma
          • Charleston, South Carolina
            Medical University of South Carolina
          2022-03-31
          Mar 31, 2022
          N
          Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma - 2021
          Completed
          • Relapsed Non Hodgkin Lymphoma
          • Refractory Lymphoma
            • Taipei, Taiwan
              National Taiwan University Hospital
            2021-08-08
            Aug 8, 2021